XNAS · Healthcare · Biotechnology
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.43 | -0.40 | +6.98% | $3.0M | ✅ Beat | +0.84% | +5.83% | — |
| 2026-02-18 | Q4 2025 | -0.38 | -0.63 | -65.79% | $32,000 | ❌ Miss | +0.00% | -2.10% | -19.07% |
| 2025-11-05 |
| Q3 2025 |
| -0.36 |
| -0.61 |
| -69.44% |
| $348,000 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.46 | -0.15 | +67.39% | $19.1M | ✅ Beat | +2.53% | +9.06% | +14.31% |
| 2025-02-26 | Q4 2024 | — | -0.51 | — | $8.6M | — | +6.09% | +16.79% | +10.40% |
Showing last 5 quarters.